Literature DB >> 14991953

Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection.

Chuan-Yong Guo1, Yun-Bin Wu, Heng-Lu Liu, Jian-Ye Wu, Min-Zhang Zhong.   

Abstract

AIM: To evaluate clinical efficacy of four one-week triple therapies in eradicating Helicobacter pylori infection.
METHODS: In this clinical trial, 132 patients with duodenal ulcer and chronic gastritis were randomly divided into four groups, and received treatment with OAC (omeprazole 20 mg + amoxicillin 1 000 mg + clarithromycin 250 mg), OFC (omeprazole 20 mg + furazolidone 100 mg + clarithromycin 250 mg), OFA (omeprazole 20 mg + furazolidone 100 mg + amoxicillin 1 000 mg) and OMC (omeprazole 20 mg + metronidazole 200 mg + clarithromycin 250 mg), respectively. Each drug was taken twice daily for one week. The (13)C urea breath test was carried out 4-8 weeks after treatment to determine the success of H pylori eradication.
RESULTS: A total of 127 patients completed the treatment. The eradication rate for H pylori infection was 90.3%, 90.9%, 70.9% and 65.6%, respectively in OAC, OFC OMC and OFA groups.
CONCLUSION: A high eradication rate can be achieved with one-week OAC or OFC triple therapy. Thus, one-week triple therapies with OAC and OFC are recommended for Chinese patients with duodenal ulcers and chronic gastritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991953      PMCID: PMC4716924          DOI: 10.3748/wjg.v10.i5.747

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

Review 1.  [How to treat after Helicobacter pylori eradication failure?].

Authors:  Stanislas Bruley des Varannes
Journal:  Gastroenterol Clin Biol       Date:  2003-03

2.  Antibiotic susceptibility of Helicobacter pylori in the Chinese population.

Authors:  J Yakoob; X Fan; G Hu; L Liu; Z Zhang
Journal:  J Gastroenterol Hepatol       Date:  2001-09       Impact factor: 4.029

3.  Amplified fragment length polymorphism genotyping of metronidazole-resistant Helicobacter pylori infecting dyspeptics in England.

Authors:  R J Owen; M Ferrus; J Gibson
Journal:  Clin Microbiol Infect       Date:  2001-05       Impact factor: 8.067

4.  The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy.

Authors:  S J Zanten; M Bradette; A Farley; D Leddin; T Lind; P Unge; E Bayerdörffer; R C Spiller; C O'Morain; P Sipponen; M Wrangstadh; L Zeijlon; P Sinclair
Journal:  Aliment Pharmacol Ther       Date:  1999-03       Impact factor: 8.171

5.  Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication.

Authors:  I J Choi; H C Jung; K W Choi; J H Kim; D S Ahn; U S Yang; J S Rew; S I Lee; J C Rhee; I S Chung; J M Chung; W-S Hong
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

6.  Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.

Authors:  T Lind; S Veldhuyzen van Zanten; P Unge; R Spiller; E Bayerdörffer; C O'Morain; K D Bardhan; M Bradette; N Chiba; M Wrangstadh; C Cederberg; J P Idström
Journal:  Helicobacter       Date:  1996-09       Impact factor: 5.753

7.  One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study.

Authors:  J J Sung; F K Chan; J C Wu; W K Leung; R Suen; T K Ling; Y T Lee; A F Cheng; S C Chung
Journal:  Aliment Pharmacol Ther       Date:  1999-08       Impact factor: 8.171

8.  Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000.

Authors:  Kathlen Wolle; Andreas Leodolter; Peter Malfertheiner; Wolfgang König
Journal:  J Med Microbiol       Date:  2002-08       Impact factor: 2.472

9.  Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.

Authors:  V Isakov; I Domareva; L Koudryavtseva; I Maev; Z Ganskaya
Journal:  Aliment Pharmacol Ther       Date:  2002-07       Impact factor: 8.171

10.  One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.

Authors:  X Calvet; J Ducons; J Guardiola; L Tito; V Andreu; F Bory; R Guirao
Journal:  Aliment Pharmacol Ther       Date:  2002-07       Impact factor: 8.171

View more
  9 in total

Review 1.  Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis.

Authors:  Ben Wang; Zhi-Fa Lv; You-Hua Wang; Hui Wang; Xiao-Qun Liu; Yong Xie; Xiao-Jiang Zhou
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 2.  Pathogenesis of Helicobacter pylori infection.

Authors:  Johannes G Kusters; Arnoud H M van Vliet; Ernst J Kuipers
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 3.  A systematic review of treating Helicobacter pylori infection with Traditional Chinese Medicine.

Authors:  Jiang Lin; Wei-Wen Huang
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

Review 4.  [Eradication and chronic acid suppression. Advances and pseudo-advances].

Authors:  S Turi; D Schilling; J F Riemann
Journal:  Internist (Berl)       Date:  2004-11       Impact factor: 0.743

5.  Drug utilization of clarithromycin for gastrointestinal disease treatment.

Authors:  Quan Zhou; Ling-Ling Zhu; Xiao-Feng Yan; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

Review 6.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

7.  Modified Sequential Therapy Regimen versus Conventional Triple Therapy for Helicobacter Pylori Eradication in Duodenal Ulcer Patients in China: A Multicenter Clinical Comparative Study.

Authors:  Ying-Qun Zhou; Ling Xu; Bing-Fang Wang; Xiao-Ming Fan; Jian-Ye Wu; Chun-Yan Wang; Chuan-Yong Guo; Xuan-Fu Xu
Journal:  Gastroenterol Res Pract       Date:  2011-11-21       Impact factor: 2.260

8.  Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis.

Authors:  Chao-Ran Ji; Jing Liu; Yue-Yue Li; Chuan-Guo Guo; Jun-Yan Qu; Yan Zhang; Xiuli Zuo
Journal:  BMJ Open       Date:  2020-10-19       Impact factor: 2.692

9.  Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy.

Authors:  Fernando M Silva; Jaime N Eisig; Ana Cristina S Teixeira; Ricardo C Barbuti; Tomás Navarro-Rodriguez; Rejane Mattar
Journal:  BMC Gastroenterol       Date:  2008-05-29       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.